Drug misuse and dependency

Transparency and freedom of information releases

sorted by Updated (newest)
  1. Commissioning impact on drug treatment

    This report by the Advisory Council on the Misuse of Drugs (ACMD) investigates the impact on drug treatment.

  2. Psychoactive Substances Bill: evaluation review

    An evaluation review of the Psychoactive Substances Bill by the Advisory Council on the Misuse of Drugs (ACMD).

  3. Drug strategy 2016: development review

    A review of the evidence on the 2016 drug strategy by the Advisory Council on the Misuse of Drugs (ACMD).

  4. Methiopropamine: a review of the evidence of use and harm

    A review of the evidence of use and harm of Methiopropamine (MPA) by the Advisory Council on the Misuse of Drugs (ACMD).

  5. Methylphenidate base and methylphenidate hydrochloride importation, 2010 to 2012

    Figures on methylphenidate base and methylphenidate hydrochloride importation between 2010 and 2012 were requested.

  6. FRANK drugs advisory service (17080)

    Information regarding various aspects of the FRANK drugs advisory service.

  7. Decision to downgrade cannabis from class B to class C drug

    Request for details of the background that led to David Blunkett's decision to downgrade cannabis from a class B drug to a class C drug.